Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Autor: Ibrahim Yakoub-Agha, Hélène Labussière-Wallet, Max Christopeit, Francesco Lanza, Ram Malladi, Didier Blaise, Edouard Forcade, Sébastien Maury, Jan J. Cornelissen, N. Russel, Arnon Nagler, Myriam Labopin, Tobias Gedde-Dahl, Gorin Nc, Mohamad Mohty, Jakob Passweg, Emmanuelle Polge, Thomas Pabst, Gérard Socié

Publikováno v: Biology of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, 2020, 26 (4), pp.659-664. ⟨10.1016/j.bbmt.2019.11.021⟩
Biology of Blood and Marrow Transplantation, 26(4), 659-664. Elsevier Inc.
Biology of Blood and Marrow Transplantation, Elsevier, 2020, 26 (4), pp.659-664. ⟨10.1016/j.bbmt.2019.11.021⟩

After autologous hematopoietic cell transplantation (HCT) in the first complete remission (CR1), patients with acute myeloid leukemia (AML) may relapse and undergo allogeneic HCT in the second complete remission (CR2). The aim of this study was to an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17c4ac696c8ea19803a54cf92cb9a10d
https://hal-amu.archives-ouvertes.fr/hal-03152838

Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Autor: Giebel, S, Marks, DI, Boissel, N, Baron, F, Chiaretti, S, Ciceri, F, Cornelissen, JJ, Doubek, M, Esteve, J, Fielding, A, Foa, R, Gorin, NC, Gokbuget, N, Hallbook, H, Hoelzer, D, Paravichnikova, E, Ribera, JM, Savani, B, Rijneveld, AW, Schmid, C, Wartiovaara-Kautto, U, Mohty, M, Nagler, A, Dombret, H

Publikováno v: Bone Marrow Transplantation
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission is a standard of care for adult patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) and high risk of relapse. However, the strati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::25592c05ae0d2fe9e296f2d7d75cbd4d
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3078

A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia

Autor: William Arcese, He Huang, Johanna Tischer, Yener Koc, Andrea Bacigalupo, Stella Santarone, Gorin Nc, Mohamad Mohty, Myriam Labopin, Dietrich W. Beelen, G. Ehninger, Arnon Nagler, Simona Piemontese, Fabio Ciceri, Depei Wu

Publikováno v: Leukemia. 29(5)

The use of unmanipulated graft is increasingly adopted in the setting of allogeneic hematopoietic stem cell transplantation from haploidentical family donors (haplo-SCT) in acute leukemia (AL). We analyzed the outcome of 229 adult patients with de no

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c39c96093536a7c17b8382f554e395d4
https://pubmed.ncbi.nlm.nih.gov/25434302

Influence des polypathologies sur le traitement des hémopathies malignes

Autor: Gorin Nc, Andre K, Najman A

Publikováno v: Bulletin du Cancer. 96:563-570

Comorbidities are often present in adult patients treated for malignant hematological diseases. In older patients, these disabilities can have an influence on the natural course of the malignant disease, on the tolerance to treatment and clinical dec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cfc41c05b5bd4cbde4109ba6d123be75
https://doi.org/10.1684/bdc.2009.0857

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial

Autor: Je-Hwan Lee, Yoo-Jin Kim, Tzeon Jye Chiou, John Feigert, John M. Bennett, Marco Ruggeri, Amit Verma, Gorin Nc, Uwe Platzbecker, Geoffrey W. Chan, Souria Dougherty, Nicole L. Stone, Gregory Cheng, Camille N. Abboud, Raymond S.M. Wong, Suman Kambhampati, Jun Ho Jang, Frank L. Mannino, Aristoteles Giagounidis, Chien Yuan Chen, Roger M. Lyons, Sergio Araujo, Peter L. Greenberg, Shih-Peng Yeh, Yasser Mostafa Kamel, Katharina Götze, Valeria Santini, Brendan M. Johnson

Publikováno v: The Lancet. Haematology. 2(10)

Summary Background Patients with myelodysplastic syndrome or acute myeloid leukaemia who are thrombocytopenic and unable to receive disease-modifying therapy have few treatment options. Platelet transfusions provide transient benefit and are limited

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2043d33c8504613e36e7498d03e0294
https://pubmed.ncbi.nlm.nih.gov/26686035